Arcus Biosciences Hits New 52-Week High of $31.42, Up 88%

Arcus Biosciences, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 31.42 on June 25, 2026. This achievement marks a remarkable increase from its 52-week low of USD 7.91, reflecting an impressive one-year performance of 88.0%, significantly outpacing the S&P 500's performance of 20.77%. With a market capitalization of USD 2,542 million, Arcus Biosciences operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics indicate a challenging landscape, with a negative return on equity of -55.94% and a debt-to-equity ratio of -1.38. Additionally, the company does not offer a dividend, and its price-to-book ratio stands at 4.03. As Arcus Biosciences continues to navigate the complexities of the biotechnology field, this new price high underscores its recent performance trajectory and market positioning within the industry.